Neumora Therapeutics IPO Presentation Deck

NMRA-511: V1aR Antagonist Broad Potential Across Neuropsychiatric Disorders Pharmacology Antagonist of vasopressin 1a receptor (V1aR), with high selectivity over V1b, V2 (greater than 3,000-fold) and oxytocin receptors (approximately 300-fold) Vasopressin plays a role in the regulation of aggression, affiliation, stress and anxiety response Indication Agitation in Alzheimer's disease Status Conducting Phase 1 Multiple Ascending Dose (MAD) study in human healthy volunteers Drug Profile Oral, once-daily Strong IP Protection Expect exclusivity through 2042+, based on composition of matter protection and estimated patent term extension Strong Biologic Activity Demonstrated NMRA-511 reduced measures of anxiety in an NHP preclinical model, with a corresponding EEG signature in Phase 1 V1aR EXPRESSION HPC-O CeA- ECM -Lateral Neuron cytoplasm septum Expressed in multiple brain regions -BNST -A/LHy V1aR Gq/11 Endogenous pathways Enhanced in disease Drug impact Antagonist of V1aR PLC signaling cascade IP₁ DAG NMRA-511 The vasopressin system acting through V1aR modulates anxiety and threat-related behaviors, aggression and social-emotional processing Increased intracellular Ca2+ PKC PKC activation and translocation to membrane Confidential 17

View entire presentation